Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 26, No 9 (March 20), 2008: pp. 1489-1495
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.15.1126

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koopmans, K. P.
Right arrow Articles by de Vries, E. G.E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koopmans, K. P.
Right arrow Articles by de Vries, E. G.E.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*5-HYDROXYTRYPTOPHAN
Medline Plus Health Information
*Carcinoid Tumors
*CT Scans
*Nuclear Scans
*Pancreatic Cancer
Related Articles
Right arrowRelated Correspondence
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Improved Staging of Patients With Carcinoid and Islet Cell Tumors With 18F-Dihydroxy-Phenyl-Alanine and 11C-5-Hydroxy-Tryptophan Positron Emission Tomography

Klaas P. Koopmans, Oliver C. Neels, Ido P. Kema, Philip H. Elsinga, Wim J. Sluiter, Koen Vanghillewe, Adrienne H. Brouwers, Pieter L. Jager, Elisabeth G.E. de Vries

From the Departments of Nuclear Medicine and Molecular Imaging, Medical Oncology, Pathology and Laboratory Medicine, and Endocrinology, University Medical Center Groningen, University of Groningen; Department of Radiology, Martini Hospital Groningen, the Netherlands

Corresponding author: Elisabeth G.E. de Vries, MD, PhD, Department of Medical Oncology, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, the Netherlands, e-mail: e.g.e.de.vries{at}int.umcg.nl

Purpose To evaluate and compare diagnostic sensitivity of positron emission tomography (PET) scanning in carcinoid and islet cell tumor patients with a serotonin and a catecholamine precursor as tracers.

Patients and Methods Carcinoid (n = 24) or pancreatic islet cell tumor (n = 23) patients with at least one lesion on conventional imaging including somatostatin receptor scintigraphy (SRS) and computed tomography (CT) scan underwent 11C-5-hydroxytryptophan (11C-5-HTP) PET and 6-[F-18]fluoro-L-dihydroxy-phenylalanin (18F-DOPA) PET. PET findings were compared with a composite reference standard derived from all available imaging along with clinical and cytologic/histologic information.

Results In carcinoid tumor patients, per-patient analysis showed sensitivities for 11C-5-HTP PET, 18F-DOPA PET, SRS, and CT of 100%, 96%, 86%, 96%, respectively, and in islet cell tumors of 100%, 89%, 78%, 87%, respectively. In carcinoid patients, per-lesion analysis revealed sensitivities for 11C-5-HTP PET, 11C-5-HTP PET/CT, 18F-DOPA PET, 18F-DOPA PET/CT, SRS, SRS/CT, and CT alone of, respectively, 78%, 89%, 87%, 98%, 49%, 73%, and 63% and in islet cell tumors of 67%, 96%, 41%, 80%, 46%, 77%, and 68%, respectively. In all carcinoid patients 18F-DOPA PET and 11C-5-HTP PET detected more lesions than SRS (P < .001). 11C-5-HTP PET was superior to 18F-DOPA PET in islet cell tumors (P < .0001). In all cases, CT improved the sensitivity of the nuclear scans.

Conclusion 18F-DOPA PET/CT is the optimal imaging modality for staging in carcinoid patients and 11C-5-HTP PET/CT in islet cell tumor patients.

Supported by Grant No. 2003-2936 from the Dutch Cancer Society.

Presented in part at the 54th Annual Meeting of the Society of Nuclear Medicine June 2-6, 2007, Washington, DC.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Correspondence

  • Premedication With Carbidopa Masks Positive Finding of Insulinoma and β-Cell Hyperplasia in [18F]-Dihydroxy-Phenyl-Alanine Positron Emission Tomography
    Saila Kauhanen, Marko Seppänen, and Pirjo Nuutila
    JCO 2008 26: 5307-5308 [Full Text]


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
H.-B. Fiebrich, A. H. Brouwers, M. N. Kerstens, M. E. J. Pijl, I. P. Kema, J. R. de Jong, P. L. Jager, P. H. Elsinga, R. A. J. O. Dierckx, J. E. van der Wal, et al.
6-[F-18]Fluoro-L-Dihydroxyphenylalanine Positron Emission Tomography Is Superior to Conventional Imaging with 123I-Metaiodobenzylguanidine Scintigraphy, Computer Tomography, and Magnetic Resonance Imaging in Localizing Tumors Causing Catecholamine Excess
J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3922 - 3930.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Montravers, K. Kerrou, V. Nataf, V. Huchet, J.-P. Lotz, P. Ruszniewski, P. Rougier, F. Duron, P. Bouchard, J.-D. Grange, et al.
Impact of Fluorodihydroxyphenylalanine-(18F) Positron Emission Tomography on Management of Adult Patients with Documented or Occult Digestive Endocrine Tumors
J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1295 - 1301.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
H.-B. Fiebrich, A. H. Brouwers, L. van Bergeijk, and G. van den Berg
Localization of an Adrenocorticotropin-Producing Pheochromocytoma Using 18F-Dihydroxyphenylalanine Positron Emission Tomography
J. Clin. Endocrinol. Metab., March 1, 2009; 94(3): 748 - 749.
[Full Text] [PDF]


Home page
Endocr Relat CancerHome page
S. Kauhanen, M. Seppanen, J. Ovaska, H. Minn, J. Bergman, P. Korsoff, P. Salmela, J. Saltevo, T. Sane, M. Valimaki, et al.
The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors
Endocr. Relat. Cancer, March 1, 2009; 16(1): 255 - 265.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
S. N. Pinchot, K. Holen, R. S. Sippel, and H. Chen
Carcinoid Tumors
Oncologist, December 1, 2008; 13(12): 1255 - 1269.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
I. P. Kema, K.-P. Koopmans, P. H. Elsinga, A. H. Brouwers, P. L. Jager, and E. G.E. de Vries
In Reply:
J. Clin. Oncol., November 10, 2008; 26(32): 5308 - 5309.
[Full Text] [PDF]


Home page
JCOHome page
S. Kauhanen, M. Seppanen, and P. Nuutila
Premedication With Carbidopa Masks Positive Finding of Insulinoma and {beta}-Cell Hyperplasia in [18F]-Dihydroxy-Phenyl-Alanine Positron Emission Tomography
J. Clin. Oncol., November 10, 2008; 26(32): 5307 - 5308.
[Full Text] [PDF]


Home page
CirculationHome page
H.-B. Fiebrich, A. H. Brouwers, T. P. Links, and E. G.E. de Vries
Myocardial Metastases of Carcinoid Visualized by 18F-Dihydroxy-Phenyl-Alanine Positron Emission Tomography
Circulation, October 7, 2008; 118(15): 1602 - 1604.
[Full Text] [PDF]


Home page
Eur J EndocrinolHome page
P. Burman, A. Lethagen, K. Ivancev, L. Johansson, and A. Sundin
Dual bronchial carcinoids and Cushing's syndrome with a paradoxical response to dexamethasone and a false positive outcome of inferior petrosal sinus sampling
Eur. J. Endocrinol., October 1, 2008; 159(4): 483 - 488.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Leboulleux, C. Dromain, A. L. Vataire, D. Malka, A. Auperin, J. Lumbroso, P. Duvillard, D. Elias, D. M. Hartl, T. De Baere, et al.
Prediction and Diagnosis of Bone Metastases in Well-Differentiated Gastro-Entero-Pancreatic Endocrine Cancer: A Prospective Comparison of Whole Body Magnetic Resonance Imaging and Somatostatin Receptor Scintigraphy
J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 3021 - 3028.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
K. P. Koopmans, P. L. Jager, I. P. Kema, M. N. Kerstens, F. Albers, and R. P.F. Dullaart
111In-Octreotide Is Superior to 123I-Metaiodobenzylguanidine for Scintigraphic Detection of Head and Neck Paragangliomas
J. Nucl. Med., August 1, 2008; 49(8): 1232 - 1237.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online